Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i> -Amplified Breast CancersMeghan M. Joly, Rebecca S. Cook, Donna J. Hicks et al.|Cancer Research|2016Cited by 83
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and SurvivalThomas A. Werfel, Craig L. Duvall, Shan Wang et al.|Cancer Research|2018Cited by 82
Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasisMeghan M. Joly, Rebecca S. Cook, Michelle M. Williams et al.|Breast Cancer Research|2017Cited by 79
Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL BlockadeMichelle M. Williams, Rebecca S. Cook, Linus Lee et al.|Molecular Cancer Research|2016Cited by 55
ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactationMichelle M. Williams, Rebecca S. Cook, David Vaught et al.|Breast Cancer Research|2017Cited by 29